Steven Cohen’s Arbutus Biopharma ABUS Stock Holding History

Steven Cohen’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-105,000	Closed	-$263K	–	2117
2023 Q4	$263K	Buy	+105,000	New	+$206K	﹤0.01%	1734
2021 Q4	–	Sell	-895,200	Closed	-$3.84M	–	1062
2021 Q3	$3.84M	Sell	895,200 -104,800	-10%	-$349K	0.02%	708
2021 Q2	$3.03M	Sell	1,000,000 -37,700	-4%	-$117K	0.01%	685
2021 Q1	$3.46M	Buy	+1,037,700	New	+$4M	0.02%	646
2020 Q1	–	Sell	-1,897,284	Closed	-$5.27M	–	749
2019 Q4	$5.27M	Buy	+1,897,284	New	+$3.07M	0.03%	491
2017 Q4	–	Sell	-224,655	Closed	-$1.39M	–	881
2017 Q3	$1.39M	Buy	+224,655	New	+$961K	0.01%	710
2015 Q3	–	Sell	-360,800	Closed	-$4.28M	–	746
2015 Q2	$4.28M	Buy	360,800 +203,600	+130%	+$3.1M	0.03%	470
2015 Q1	$2.75M	Buy	+157,200	New	+$3.22M	0.02%	525

Other funds holding ABUS

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's ABUS Position: Q1 2024 in Review

Steven Cohen sold out of Arbutus Biopharma (ABUS) in Q1 2024, closing a stake of 105,000 shares — an estimated $263K sold.

Steven Cohen first reported a position in ABUS in Q1 2015 and held it in 8 quarters. The position peaked at $5.27M in Q4 2019. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2024.

Steven Cohen reported no remaining Arbutus Biopharma position as of Q1 2024 after selling out during the quarter.
Steven Cohen sold 105,000 Arbutus Biopharma shares in Q1 2024, an estimated $263K.
Steven Cohen first reported a position in Arbutus Biopharma in Q1 2015 and held it in 8 quarters.
Steven Cohen's Arbutus Biopharma position peaked at $5.27M in Q4 2019.
119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2024.

Based on Point72 Asset Management's 13F filing for Q1 2024, filed 15 May 2024.